Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension

被引:1
作者
Idrees, Majdy M. [1 ]
Swiston, John [2 ]
Nizami, Imran [3 ]
Al Dalaan, Abdullah [4 ]
Levy, Robert D. [2 ]
机构
[1] Prince Sultan Med Mil City, Pulm Med, Riyadh 11159, Saudi Arabia
[2] Vancouver Gen Hosp, Vancouver, BC, Canada
[3] King Faisal Specialist Hosp & Res Ctr, Dept Organs Transplant, Riyadh 11211, Saudi Arabia
[4] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
关键词
Specific therapy; target therapy; pulmonary arterial hypertension; lung transplant; Saudi association for pulmonary hypertension guidelines; ENDOTHELIN-RECEPTOR ANTAGONIST; CONTINUOUS INTRAVENOUS EPOPROSTENOL; RANDOMIZED CONTROLLED-TRIAL; CONGENITAL HEART-DEFECTS; CALCIUM-CHANNEL BLOCKERS; PLACEBO-CONTROLLED TRIAL; INHALED NITRIC-OXIDE; LONG-TERM TREATMENT; ADD-ON THERAPY; LUNG-TRANSPLANTATION;
D O I
10.4103/1817-1737.134043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Prior to the availability of the pulmonary arterial hypertension (PAH)-specific therapy, PAH was a dreadful disease with a very poor prognosis. Better understanding of the complex pathobiology of PAH has led to a major therapeutic evolution. International regulatory agencies have approved many specific drugs with different pharmacologic pathways and routes of administration. In the year 2013, two new drugs with great potentials in managing PAH have been added to the treatment options, macitentan and riociguat. Additional drugs are expected to come in the near future. A substantial body of evidence has confirmed the effectiveness of pulmonary arterial hypertension (PAH)-specific therapies in improving the patients symptomatic status and slowing down the rate of clinical deterioration. the newer modern medications have significantly improved the survival of patients with PAH, it remains a non-curable and fatal disease. Lung transplantation (LT) remains the only therapeutic option for selected patients with advanced disease who continue to deteriorate despite optimal therapy.
引用
收藏
页码:79 / 91
页数:13
相关论文
共 102 条
[1]   Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension [J].
Aguilar, RV ;
Farber, HW .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (05) :1846-1850
[2]   CORRECTION [J].
AHN, HS .
ELECTRONICS LETTERS, 1991, 27 (02) :191-191
[3]   EXPERIMENTAL STUDIES OF SURGICAL TREATMENT OF PRIMARY PULMONARY HYPERTENSION [J].
AUSTEN, WG ;
BERRY, WB ;
MORROW, AG .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1964, 48 (03) :448-+
[4]  
Bachetti C, 2013, AM J RESP CRIT CARE, V187
[5]   Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].
Badesch, DB ;
Tapson, VF ;
McGoon, MD ;
Brundage, BH ;
Rubin, LJ ;
Wigley, FM ;
Rich, S ;
Barst, RJ ;
Barrett, PS ;
Kral, KM ;
Jöbsis, MM ;
Loyd, JE ;
Murali, S ;
Frost, A ;
Girgis, R ;
Bourge, RC ;
Ralph, DD ;
Elliott, CG ;
Hill, NS ;
Langleben, D ;
Schilz, RJ ;
McLaughlin, VV ;
Robbins, IM ;
Groves, BM ;
Shapiro, S ;
Medsger, TA ;
Gaine, SP ;
Horn, E ;
Decker, JC ;
Knobil, K .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+
[6]   Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil [J].
Barst, R. J. ;
Galie, N. ;
Naeije, R. ;
Simonneau, G. ;
Jeffs, R. ;
Arneson, C. ;
Rubin, L. J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (06) :1195-1203
[7]   Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension [J].
Barst, RJ ;
Ivy, D ;
Dingemanse, J ;
Widlitz, A ;
Schmitt, K ;
Doran, A ;
Bingaman, D ;
Nguyen, N ;
Gaitonde, M ;
van Giersbergen, PLM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (04) :372-382
[8]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[9]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125
[10]   A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension [J].
Barst, Robyn J. ;
Ivy, D. Dunbar ;
Gaitan, Guillermo ;
Szatmari, Andras ;
Rudzinski, Andrzej ;
Garcia, Alberto E. ;
Sastry, B. K. S. ;
Pulido, Tomas ;
Layton, Gary R. ;
Serdarevic-Pehar, Marjana ;
Wessel, David L. .
CIRCULATION, 2012, 125 (02) :324-334